0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Communication |

Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications

Matthew J. Sheetz, MD, PhD; George L. King, MD
JAMA. 2002;288(20):2579-2588. doi:10.1001/jama.288.20.2579.
Text Size: A A A
Published online

Diabetic complications are the major cause of morbidity and mortality in persons with diabetes. Chronic hyperglycemia is a major initiator of diabetic microvascular complications (eg, retinopathy, neuropathy, nephropathy). Glucose processing uses a variety of diverse metabolic pathways; hence, chronic hyperglycemia can induce multiple cellular changes leading to complications. Several predominant well-researched theories have been proposed to explain how hyperglycemia can produce the neural and vascular derangements that are hallmarks of diabetes. These theories can be separated into those that emphasize the toxic effects of hyperglycemia and its pathophysiological derivatives (such as oxidants, hyperosmolarity, or glycation products) on tissues directly and those that ascribe pathophysiological importance to a sustained alteration in cell signaling pathways (such as changes in phospholipids or kinases) induced by the products of glucose metabolism. This article summarizes these theories and the potential therapeutic interventions that may prevent diabetic complications in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Figure 1. Overall Categorization of Signaling Pathways Involved in Diabetic Complications
Graphic Jump Location
AR indicates aldose reductase; RAGE, receptor for advanced glycation endproducts; PKC, protein kinase C.
Figure 2. Aldose Reductase Pathway Theory
Graphic Jump Location
NADPH indicates reduced nicotinamide-adenine dinucleotide phosphate; NADP+, oxidized nicotinamide-adenine dinucleotide phosphate; NAD+, oxidized nicotinamide adenine dinucleotide; and NADH, reduced nicotinamide adenine dinucleotide.
Figure 3. Advanced Glycation Endproduct (AGE) Pathway Theory
Graphic Jump Location
Figure 4. Reactive Oxygen Intermediate Pathway Theory
Graphic Jump Location
AGE indicates advanced glycation endproduct; oxLDL, oxidized low-density lipoprotein; GSH, glutathione; GSSG, glutathione disulfide; and NADPH, nicotinamide-adenine dinucleotide phosphate.
Figure 5. Protein Kinase C Theory
Graphic Jump Location
OXPHOS indicates oxidative phosphorylation; ROI, reactive oxygen intermediate; AGE, advanced glycation endproduct; and NADPH, nicotinamide-adenine dinucleotide phosphate.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 369

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
VAP-1 in peritoneally dialyzed patients. Postepy Hig Med Dosw (Online) 2013;67():1340-4.
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2014;306(9):F1008-17.
Jobs
brightcove.createExperiences();